| Literature DB >> 32328460 |
Yiying Zhang1, Kan He1, Yan Guo2, Xiangchun Liu1, Qi Yang1, Chunyu Zhang1, Yunming Xie1, Shengnan Mu1, Yu Guo1, Yu Fu1, Huimao Zhang1.
Abstract
Objective: To explore a new predictive model of lymphatic vascular infiltration (LVI) in rectal cancer based on magnetic resonance (MR) and computed tomography (CT).Entities:
Keywords: MRI; computed tomography; lymphovascular invasion; multimodal imaging; nomogram; radiomics; rectal cancer
Year: 2020 PMID: 32328460 PMCID: PMC7160379 DOI: 10.3389/fonc.2020.00457
Source DB: PubMed Journal: Front Oncol ISSN: 2234-943X Impact factor: 6.244
Figure 1Flow diagram of patient selection.
Figure 2Framework of this study. A flowchart describing the radiomics method for LVI of rectal cancer prediction.
Clinical characteristics and radiomics score of the training and validation cohort for lymphovascular invasion of rectal cancer.
| Age (Mean ± SD) | 59.56 ± 10.96 | 60.61 ± 13.18 | 0.541 | 55.57 ± 14.12 | 58.73 ± 12.62 | 0.718 | |
| Gender (No., %) | Male | 22 (68.75) | 25 (75.76) | 0.535 | 12 (85.71) | 12 (80.00) | 0.697 |
| Female | 10 (31.25) | 8 (24.24) | 2 (15.29) | 3 (20.00) | |||
| CEA (ng/ml, %) | Normal | 19 (59.38) | 16 (48.48) | 0.386 | 6 (42.86) | 8 (53.33) | 0.589 |
| Abnormal | 13 (40.62) | 17 (51.52) | 8 (57.14) | 7 (46.67) | |||
| CA-199 (ng/ml, %) | Normal | 24 (75.00) | 28 (84.85) | 0.329 | 12 (85.71) | 12 (80.00) | 0.697 |
| Abnormal | 8 (25.00) | 5 (15.15) | 2 (14.29) | 3 (20.00) | |||
| CT_Score [Median (25, 75%)] | 1.222 (−0.158, 2.918) | −0.911 (−2.456, 0.599) | <0.001 | 1.530 (0.835, 2.170) | −1.684 (−4.073, −0.145) | 0.002 | |
| DWI_Score [Median (25, 75%)] | 0.468 (−0.005, 1.259) | 0.070 (−0.593, 0.500) | 0.012 | 0.232 (−0.037, 0.509) | −0.354 (−1.826, −0.176) | 0.002 | |
| T2_Score [Median (25, 75%)] | 0.331 (−0.057, 0.724) | −0.268 (−1.106, 0.184) | 0.002 | 0.528 (0.193, 0.808) | −0.374 (−0.780, 0.223) | 0.063 | |
| Rad-score A [Median (25, 75%)] | 1.678 (0.232, 2.380) | −1.411 (−2.391, −0.628) | <0.001 | 0.657 (0.583, 1.565) | −2.510 (−3.41, −1.38) | <0.001 | |
| Rad-score B [Median (25, 75%)] | 0.529 (−0.215, 0.753) | −0.485 (−1.096, 0.035) | <0.001 | 0.488 (−0.088, 0.780) | −0.291 (−1.164, 0.277) | 0.018 | |
| pT stage | T1-2 | 3 (9.38) | 19 (57.58) | <0.001 | 1 (7.14) | 0 (0.00) | 0.168 |
| T3-4 | 29 (90.62) | 14 (42.42) | 13 (92.86) | 15 (100.00) | |||
| pN stage | N0 | 0 (0.00) | 32 (96.97) | <0.001 | 0 (0.00) | 14 (93.33) | <0.001 |
| N1-2 | 32 (100.00) | 1 (3.03) | 14 (100.00) | 1 (6.67) | |||
| Tumor length (Mean ± SD) | 5.57 ± 2.36 | 5.89 ± 2.26 | 0.447 | 5.32 ± 1.59 | 5.32 ± 1.95 | 0.856 | |
| Tumor thickness (Mean ± SD) | 1.56 ± 0.79 | 1.50 ± 0.78 | 0.419 | 1.30 ± 0.37 | 1.45 ± 0.55 | 0.493 | |
| T2WI_volume (mm3) [Median (25, 75%)] | 7558.770 (4257.333, 11021.175) | 5934.650 (3059.595, 11771.650) | 0.550 | 6097.545 (2727.905, 7122.2125) | 7244.400 (3876.030, 10126.800) | 0.346 | |
| DWI_volume (mm3) [Median (25, 75%)] | 7492.685 (4209.595, 9908.308) | 6503.910 (2510.985, 13763.400) | 0.659 | 4833.990 (3279.730, 7781.370) | 7009.280 (4028.330, 10527.300) | 0.167 | |
| CT_volume (mm3) [Median (25, 75%)] | 9748.935 (6104.673, 5280.300) | 12227.700 (4606.160, 16144.450) | 0.959 | 8004.380 (3894.278, 10866.125) | 11366.800 (7116.990, 17447.800) | 0.181 | |
LVI, lymphovascular invasion; CEA, Carcinoembryonic antigen; CA-199, Carbohydrate antigen 199; Rad-score, Radiomic score; pT stage, pathological tumor stage; pN stage, pathological limph node stage.
p < 0.05 indicated significant differences.
Figure 3Area under the ROC curves of each radiomics model.
The performance of each models in the train and validation cohorts.
| CT | 0.804 (0.697–0.911) | 0.824 (0.643–1.000) | 0.545 | 0.600 | 0.969 | 0.857 | 0.754 | 0.724 | 0.336 | 0.854 |
| DWI | 0.681 (0.551–0.811) | 0.824 (0.667–0.981) | 0.939 | 1.000 | 0.375 | 0.143 | 0.662 | 0.586 | 0.594 | 0.174 |
| T2WI | 0.719 (0.591–0.846) | 0.705 (0.501–0.909) | 0.697 | 0.600 | 0.750 | 0.786 | 0.723 | 0.690 | 0.502 | 0.910 |
| Model A | 0.884 (0.803–0.964) | 0.876 (0.721–1.000) | 0.727 | 0.800 | 0.938 | 0.929 | 0.831 | 0.862 | 0.313 | 0.935 |
| Model B | 0.774 (0.654–0.894) | 0.757 (0.576–0.938) | 0.788 | 0.533 | 0.781 | 0.786 | 0.785 | 0.655 | 0.477 | 0.942 |
P was derived from Delong test between the train and validation cohorts.
Figure 4Calibration curves of the nomogram in the validation cohort. The closer fit of the diagonal curved line to the ideal straight line indicates the predictive accuracy of the nomogram from the best model. Radiomics nomogram was developed in the training cohort.
Figure 5Decision curves analysis of multimodal A and B performed in the validation cohort. The net benefit is represented on the y-axis. The threshold probability is represented on the x-axis. The net benefit of model A was higher than model B across the full range of reasonable threshold probabilities.